FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

被引：34

作者：

de la Rubia, J ^{[1
]}

Regadera, AI ^{[1
]}

Martín, G ^{[1
]}

Cervera, J ^{[1
]}

Sanz, G ^{[1
]}

Martínez, JA ^{[1
]}

Jarque, I ^{[1
]}

García, I ^{[1
]}

Andreu, R ^{[1
]}

Moscardó, F ^{[1
]}

Jiménez, C ^{[1
]}

Mollá, S ^{[1
]}

Benlloch, L ^{[1
]}

Sanz, MA ^{[1
]}

机构：

[1] Univ Hosp La Fe, Hematol Serv, Valencia, Spain

来源：

LEUKEMIA RESEARCH | 2002年 / 26卷 / 08期

关键词：

myeloid malignancies; high-risk; fludarabine; toxicity;

D O I：

10.1016/S0145-2126(02)00003-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty-five patients with high-risk myeloid malignancies (32 acute myeloid leukemia and 13 high-risk myelodysplastic syndromes) were treated with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA). Twenty-four (53%) patients achieved complete remission (CR), and five (11%) partial remission. Infection predominantly with pulmonary involvement was the most common regimen-related toxicity. Mucositis (15 patients) and pulmonary toxicity (19 patients) were the most frequently observed non-hematologic side effects. There were four early deaths and 12 patients presented with resistant disease. Overall survival (OS) at 12 months was 40%. The FLAG-IDA regimen shows evident antileukemic activity in patients with high-risk myeloid malignancies with acceptable toxicity. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：725 / 730

页数：6

共 39 条

[1]

BERMAN E, 1991, BLOOD, V77, P1666

[2] Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS [J].

Bernasconi, C ;

Alessandrino, EP ;

Bernasconi, P ;

Bonfichi, M ;

Lazzarino, M ;

Canevari, A ;

Castelli, G ;

Brusamolino, E ;

Pagnucco, G ;

Castagnola, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :678-683

[3] Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG [J].

Byrne, JL ;

Dasgupta, E ;

Pallis, M ;

Turzanski, J ;

Forman, K ;

Mitchell, D ;

Haynes, AP ;

Russell, NH .

LEUKEMIA, 1999, 13 (05) :786-791

[4]

*CANC AC LEUK GROU, 1974, CRIT EV AC LEUK LEUK

[5]

CARELLA AM, 1993, LEUKEMIA, V7, P196

[6]

CASSILETH PA, 1992, BLOOD, V79, P1924

[7] NEUROTOXICITY OF PURINE ANALOGS - A REVIEW [J].

CHESON, BD ;

VENA, DA ;

FOSS, FM ;

SORENSEN, JM .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2216-2228

[8]

Clavio M, 1996, HAEMATOLOGICA, V81, P513

[9] THE MANAGEMENT OF RECURRENT ACUTE MYELOGENOUS LEUKEMIA AT A SINGLE CENTER OVER A 15-YEAR PERIOD [J].

DAVIS, CL ;

ROHATINER, AZS ;

LIM, J ;

WHELAN, JS ;

OZA, AM ;

AMESS, J ;

LOVE, S ;

STEAD, E ;

LISTER, TA .

BRITISH JOURNAL OF HAEMATOLOGY, 1993, 83 (03) :404-411

[10]

DEWITTE T, 1995, LEUKEMIA, V9, P1805

← 1 2 3 4 →